OLMA vs. GPCR, CVAC, CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, and PAHC
Should you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.
Olema Pharmaceuticals vs. Its Competitors
Structure Therapeutics (NASDAQ:GPCR) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.
91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Structure Therapeutics has a beta of -1.87, suggesting that its share price is 287% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
Structure Therapeutics' return on equity of -16.35% beat Olema Pharmaceuticals' return on equity.
Structure Therapeutics presently has a consensus target price of $76.17, indicating a potential upside of 306.44%. Olema Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 429.16%. Given Olema Pharmaceuticals' higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Structure Therapeutics.
In the previous week, Structure Therapeutics had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Structure Therapeutics and 1 mentions for Olema Pharmaceuticals. Structure Therapeutics' average media sentiment score of 0.56 beat Olema Pharmaceuticals' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the media.
Structure Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Structure Therapeutics beats Olema Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get Olema Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Olema Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:OLMA) was last updated on 7/9/2025 by MarketBeat.com Staff
Free OLMA Stock Alerts